150 related articles for article (PubMed ID: 23232798)
21. Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.
Sato K; Mano T; Ihara R; Suzuki K; Tomita N; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; Iwatsubo T; Toda T; Iwata A;
J Alzheimers Dis; 2019; 68(2):777-788. PubMed ID: 30814351
[TBL] [Abstract][Full Text] [Related]
22. Pairwise Correlation Analysis of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Dataset Reveals Significant Feature Correlation.
Huckvale ED; Hodgman MW; Greenwood BB; Stucki DO; Ward KM; Ebbert MTW; Kauwe JSK; The Alzheimer's Disease Neuroimaging Initiative ; The Alzheimer's Disease Metabolomics Consortium ; Miller JB
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828267
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.
Aisen PS; Petersen RC; Donohue M; Weiner MW;
Alzheimers Dement; 2015 Jul; 11(7):734-9. PubMed ID: 26194309
[TBL] [Abstract][Full Text] [Related]
24. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.
Saykin AJ; Shen L; Yao X; Kim S; Nho K; Risacher SL; Ramanan VK; Foroud TM; Faber KM; Sarwar N; Munsie LM; Hu X; Soares HD; Potkin SG; Thompson PM; Kauwe JS; Kaddurah-Daouk R; Green RC; Toga AW; Weiner MW;
Alzheimers Dement; 2015 Jul; 11(7):792-814. PubMed ID: 26194313
[TBL] [Abstract][Full Text] [Related]
25. Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer's Disease Neuroimaging (ADNI) database.
Beltrán JF; Wahba BM; Hose N; Shasha D; Kline RP;
PLoS One; 2020; 15(7):e0235663. PubMed ID: 32716914
[TBL] [Abstract][Full Text] [Related]
26. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
Vasanthakumar A; Davis JW; Idler K; Waring JF; Asque E; Riley-Gillis B; Grosskurth S; Srivastava G; Kim S; Nho K; Nudelman KNH; Faber K; Sun Y; Foroud TM; Estrada K; Apostolova LG; Li QS; Saykin AJ;
Clin Epigenetics; 2020 Jun; 12(1):84. PubMed ID: 32539856
[TBL] [Abstract][Full Text] [Related]
27. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
Johnstone D; Milward EA; Berretta R; Moscato P;
PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
[TBL] [Abstract][Full Text] [Related]
28. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Salazar J; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2017 May; 13(5):561-571. PubMed ID: 27931796
[TBL] [Abstract][Full Text] [Related]
29. Neuropsychological Equivalence of the Clinical Diagnosis of Mild Cognitive Impairment in the National Alzheimer's Coordinating Center Uniform Data Set and Alzheimer's Disease Neuroimaging Initiative.
Kiselica AM; Benge JF;
Dement Geriatr Cogn Disord; 2021; 50(3):231-236. PubMed ID: 34186536
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.
Shen L; Thompson PM; Potkin SG; Bertram L; Farrer LA; Foroud TM; Green RC; Hu X; Huentelman MJ; Kim S; Kauwe JS; Li Q; Liu E; Macciardi F; Moore JH; Munsie L; Nho K; Ramanan VK; Risacher SL; Stone DJ; Swaminathan S; Toga AW; Weiner MW; Saykin AJ;
Brain Imaging Behav; 2014 Jun; 8(2):183-207. PubMed ID: 24092460
[TBL] [Abstract][Full Text] [Related]
31. Using high-dimensional machine learning methods to estimate an anatomical risk factor for Alzheimer's disease across imaging databases.
Casanova R; Barnard RT; Gaussoin SA; Saldana S; Hayden KM; Manson JE; Wallace RB; Rapp SR; Resnick SM; Espeland MA; Chen JC;
Neuroimage; 2018 Dec; 183():401-411. PubMed ID: 30130645
[TBL] [Abstract][Full Text] [Related]
32. Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).
Liu E; Luthman J; Cedarbaum JM; Schmidt ME; Cole PE; Hendrix J; Carrillo MC; Jones-Davis D; Tarver E; Novak G; De Santi S; Soares HD; Potter WZ; Siemers E; Schwarz AJ
Alzheimers Dement; 2015 Jul; 11(7):840-9. PubMed ID: 26194317
[TBL] [Abstract][Full Text] [Related]
33. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
[TBL] [Abstract][Full Text] [Related]
34. Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
Kling MA; Goodenowe DB; Senanayake V; MahmoudianDehkordi S; Arnold M; Massaro TJ; Baillie R; Han X; Leung YY; Saykin AJ; Nho K; Kueider-Paisley A; Tenenbaum JD; Wang LS; Shaw LM; Trojanowski JQ; Kaddurah-Daouk RF;
Alzheimers Dement; 2020 Sep; 16(9):1234-1247. PubMed ID: 32715599
[TBL] [Abstract][Full Text] [Related]
35. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
[TBL] [Abstract][Full Text] [Related]
36. [Alzheimer's disease Neuroimaging Initiative (ADNI)].
Iwatsubo T
Nihon Rinsho; 2011 Oct; 69 Suppl 8():570-4. PubMed ID: 22787853
[No Abstract] [Full Text] [Related]
37. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.
Beckett LA; Harvey DJ; Gamst A; Donohue M; Kornak J; Zhang H; Kuo JH;
Alzheimers Dement; 2010 May; 6(3):257-64. PubMed ID: 20451874
[TBL] [Abstract][Full Text] [Related]
38. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
[TBL] [Abstract][Full Text] [Related]
39. Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer's disease.
Zhu XC; Dai WZ; Ma T
BMC Med Genet; 2020 Sep; 21(1):181. PubMed ID: 32919460
[TBL] [Abstract][Full Text] [Related]
40. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
Wang HF; Tan L; Hao XK; Jiang T; Tan MS; Liu Y; Zhang DQ; Yu JT;
J Alzheimers Dis; 2015; 44(1):115-23. PubMed ID: 25182741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
